Neurobiology of Opioid Dependence: 3 - 3
NCT00000194 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2016-05-06
Summary
The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
Conditions
- Opioid-Related Disorders
Interventions
- DRUG
-
Cycloserine
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
collaborator NIH -
Yale University
lead OTHER
Principal Investigators
-
Marc I Rosen, M.D. · VA Connecticut Healthcare System
Study Design
- Purpose
- TREATMENT
- Masking
- DOUBLE
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1993-01-31
- Primary Completion
- 1998-01-31
- Completion
- 1998-01-31
Countries
- United States
Study Locations
More Related Trials
-
The Effects of ∆-9-THC and Naloxone in Humans
NCT01591629 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity
NCT02557984 ·Status: COMPLETED ·Phase: NA
-
Quantitative Xylazine Measurement in ED
NCT06949605 ·Status: COMPLETED
-
Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II
NCT02652195 ·Status: UNKNOWN ·Phase: PHASE2
-
Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin
NCT03011970 ·Status: COMPLETED ·Phase: PHASE1
-
tDCS to Decrease Opioid Relapse (UG3)
NCT03842137 ·Status: COMPLETED ·Phase: NA
-
The Influence of Oxytocin on Automatic Imitation Behaviour in Healthy Adults
NCT01767025 ·Status: COMPLETED ·Phase: PHASE3
-
Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development
NCT01020669 ·Status: COMPLETED
-
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
NCT02643355 ·Status: COMPLETED ·Phase: NA
-
Oxytocin Buffers Stress Response in Individuals With Impaired Coping Abilities
NCT01065610 ·Status: COMPLETED ·Phase: NA
-
Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System
NCT03854942 ·Status: TERMINATED ·Phase: PHASE1
-
Wellcome Leap Psilocybin for OUD
NCT06786325 ·Status: RECRUITING ·Phase: PHASE2
-
Endogenous Opioid Modulation by Ketamine
NCT03051945 ·Status: WITHDRAWN ·Phase: PHASE3
-
Behavior Brain Responses
NCT03964350 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of Oxytocin on Craving and Therapy Response
NCT01827332 ·Status: COMPLETED ·Phase: NA
-
Ovarian Hormones and Stress Induced Drug Craving
NCT02098434 ·Status: COMPLETED ·Phase: NA
-
Effect of Oxytocin on Stress in Marijuana Users
NCT01335789 ·Status: COMPLETED ·Phase: NA
-
Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7
NCT00000255 ·Status: COMPLETED ·Phase: PHASE2
-
Influence of Oxytocin on Resting State Neurophysiological Measures
NCT03255148 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
NCT03679949 ·Status: COMPLETED ·Phase: PHASE1
-
Reward and Drug Effects on Mood and Brain Response
NCT04512365 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neuromodulation and Cognitive Training in Opioid Use Disorder
NCT03773523 ·Status: RECRUITING ·Phase: NA
-
Dose-dependent Effects of Oxytocin on the Amygdala and Reward System
NCT03846739 ·Status: COMPLETED ·Phase: PHASE1
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
NCT04427709 ·Status: RECRUITING ·Phase: PHASE2
-
The Effects of Fentanyl Abuse on Executive Function and Related Brain Activity
NCT05469217 ·Status: UNKNOWN